AR069520A1 - Utilizacion de una cepa de l. casei para la preparacion de una composicion para inhibir la activacion de mastocitos - Google Patents

Utilizacion de una cepa de l. casei para la preparacion de una composicion para inhibir la activacion de mastocitos

Info

Publication number
AR069520A1
AR069520A1 ARP080105236A ARP080105236A AR069520A1 AR 069520 A1 AR069520 A1 AR 069520A1 AR P080105236 A ARP080105236 A AR P080105236A AR P080105236 A ARP080105236 A AR P080105236A AR 069520 A1 AR069520 A1 AR 069520A1
Authority
AR
Argentina
Prior art keywords
composition
strain
use indicated
indicated
preparation
Prior art date
Application number
ARP080105236A
Other languages
English (en)
Inventor
Cecile Schiffer-Mannioui
Sandrine Samson
Raphaelle Bourdet-Sicard
Marc Daeron
Original Assignee
Pasteur Institut
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Gervais Danone Sa filed Critical Pasteur Institut
Publication of AR069520A1 publication Critical patent/AR069520A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

Reivindicacion 1: La utilizacion de una cepa de L. casei o de una de B. breve, o de ambas cepas a la vez, para la preparacion de una composicion para inhibir la activacion de mastocitos. Reivindicacion 2: La utilizacion que se indica en la reivindicacion 1, para la preparacion de una composicion que prevenga la activacion de mastocitos inducida por la IgE. Reivindicacion 8: La utilizacion que se indica en una cualquiera de las reivindicaciones 1 a 7, que se caracteriza porque la mencionada cepa de L. casei es la cepa que se depositara en el CNCM el 30 de diciembre de 1994, bajo el numero I-1518. Reivindicacion 9: La utilizacion que se indica en una cualquiera de las reivindicaciones 1 a 8, que se caracteriza porque la mencionada cepa de Bifidobacterium breve es la cepa que se depositara en el CNCM bajo el numero I-2219, el 31 de mayo de 1999. Reivindicacion 10: La utilizacion que se indica en una cualquiera de las reivindicaciones 1 a 9, que se caracteriza porque la mencionada composicion es un suplemento alimenticio o un alimento funcional o ambas cosas a un mismo tiempo. Reivindicacion 12: La utilizacion que se indica en una cualquiera de las reivindicaciones 1 a 11, que se caracteriza porque la mencionada composicion comprende además, como mínimo, una sola cepa bacteriana más que se selecciona de entre los géneros Lactobacillus, Lactococcus y Streptococcus. Reivindicacion 13: La utilizacion que se indica en la reivindicacion 12, que se caracteriza porque la mencionada composicion comprende, como mínimo, una sola cepa bacteriana que se selecciona del grupo consistente en Streptococcus thermophilus y Lactobacillus bulgaricus. Reivindicacion 14: La utilizacion que se indica en una cualquiera de las reivindicaciones 1 a 9, 12 y 13, que se caracteriza porque la mencionada composicion es un producto medicinal. Reivindicacion 17: La utilizacion que se indica en una cualquiera de las reivindicaciones 1 a 15, que se caracteriza, porque la mencionada composicion consta de un lisado bacteriano o de una fraccion bacteriana de las mencionadas bacterias. Reivindicacion 19: Un proceso de busqueda para identificar cepas bacterianas que se pueda emplear para la preparacion de composiciones que inhiban la activacion de mastocitos por parte de anticuerpos, el mencionado proceso caracterizado por constar de las siguientes etapas: (a) incubar mastocitos con las bacterias que se ha de identificar, durante una hora como mínimo; (b) como opcion, la eliminacion de las mencionadas bacterias; (c) anadir a los mastocitos un agente activador; y (d) medir la activacion de mastocitos. Reivindicacion 20: El proceso de busqueda que se indica en la reivindicacion 19, que se caracteriza porque el agente de activacion que se usa en la etapa (c) se selecciona del grupo consistente en complejos preformados IgG / antígeno, ionoforo de calcio, LPS, PMA, ionomicina, tapsigargina y mezclas de dos o más de todos estos.
ARP080105236A 2007-11-30 2008-12-01 Utilizacion de una cepa de l. casei para la preparacion de una composicion para inhibir la activacion de mastocitos AR069520A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291431A EP2065048A1 (en) 2007-11-30 2007-11-30 Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation

Publications (1)

Publication Number Publication Date
AR069520A1 true AR069520A1 (es) 2010-01-27

Family

ID=39323735

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105236A AR069520A1 (es) 2007-11-30 2008-12-01 Utilizacion de una cepa de l. casei para la preparacion de una composicion para inhibir la activacion de mastocitos

Country Status (7)

Country Link
US (1) US20100284973A1 (es)
EP (2) EP2065048A1 (es)
JP (1) JP2011505349A (es)
CN (1) CN101909643A (es)
AR (1) AR069520A1 (es)
RU (1) RU2010126596A (es)
WO (1) WO2009068997A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924307B1 (fr) * 2007-12-04 2010-08-27 Gervais Danone Sa Utilisation de l. casei ssp. paracasei comme antifongique
WO2010013143A2 (en) * 2008-08-01 2010-02-04 Institut Pasteur Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
ES2691301T3 (es) * 2010-03-12 2018-11-26 Compagnie Gervais Danone Bacterias de ácido láctico para la enfermedad celíaca
KR101275227B1 (ko) * 2010-10-13 2013-06-18 광주과학기술원 중증근무력증 예방, 개선 또는 치료용 조성물
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN103257237B (zh) * 2013-05-09 2015-05-20 中国农业大学 一种食品中过敏原的体外检测方法
WO2016102951A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Pirin polypeptide and immune modulation
ME02997B (me) 2014-12-23 2018-10-20 4D Pharma Res Ltd Soj bacteroides thetaiotaomicron i njegova upotreba u smanjenju inflamacije
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MD3307288T2 (ro) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compoziții care conțin tulpini bacteriene
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN115364122A (zh) 2015-06-15 2022-11-22 4D制药研究有限公司 包含细菌菌株的组合物
PL3206700T3 (pl) * 2015-06-15 2019-11-29 4D Pharma Res Ltd Kompozycje zawierające szczepy bakteryjne
EA034677B1 (ru) 2015-11-20 2020-03-05 4Д Фарма Рисёрч Лимитед Композиции для лечения или профилактики рака, содержащие штамм enterococcus gallinarum
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3387156B1 (en) * 2015-12-11 2020-04-29 PrecisionBiotics Group Limited Lactobacillus casei for treating obesity and associated metabolic disorders
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
DK3313423T3 (da) 2016-03-04 2019-05-20 4D Pharma Plc Sammensætninger omfattende bakterielle blautia-stammer til behandling af visceral hypersensitivitet
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
LT3630136T (lt) 2017-05-22 2021-06-10 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
HUE052258T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Megasphaera nemzetségbe tartozó baktériumtörzset tartalmazó készítmény, és alkalmazása
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
IL283973B (en) 2017-06-14 2022-08-01 4D Pharma Res Ltd Preparations containing bacterial strains
KR102038679B1 (ko) * 2018-01-12 2019-10-30 (주)지아이이노베이션 프로바이오틱스 및 IgE에 결합능이 있는 폴리펩티드를 포함하는 조성물 및 이의 용도
CN109266584B (zh) * 2018-10-18 2020-09-08 扬州大学 一株具有肥大细胞活性调节作用的纤毛型鼠李糖乳杆菌及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617758B2 (ja) * 1988-03-25 1997-06-04 株式会社ヤクルト本社 抗体産生増強型免疫賦活剤
CN1099271A (zh) * 1993-08-23 1995-03-01 王世荣 生态口服液
CN1114354A (zh) * 1994-06-23 1996-01-03 江苏省纺织(集团)总公司实业开发分公司 双歧杆菌在含中药培养基中进行有氧发酵的方法
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
CN1289092C (zh) * 2002-10-29 2006-12-13 西安大鹏生物科技股份有限公司 一种肠道微生态调节剂
US7179460B2 (en) * 2002-12-05 2007-02-20 Danisco A/S Bacterial composition and its use
ES2314461T3 (es) * 2003-10-24 2009-03-16 N.V. Nutricia Composicion simbiotica para bebes.
CN100396771C (zh) * 2004-05-10 2008-06-25 景岳生物科技股份有限公司 新的微生物株类干酪乳杆菌gm-080及其治疗过敏相关疾病的用途
US7351572B2 (en) * 2004-10-15 2008-04-01 Genmont Biotech Inc. Microorganism strain GM-090 of Lactobacillus fermentum and its use for stimulating IFN-γ secretion and/or treating allergy
EP1683425A1 (en) * 2005-01-21 2006-07-26 Compagnie Gervais Danone Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction
US20090028840A1 (en) * 2005-09-23 2009-01-29 Gwangju Institute Of Sciecne And Technology Compositions For Preventing Or Treating Arthritis Comprising Lactic Acid Bacteria and Collangen As Active Ingredients
CN100556414C (zh) * 2005-10-14 2009-11-04 德阳创新生物工程有限公司 一种具免疫调节功能的多菌组合物及其制备方法与用途
JP2007117031A (ja) * 2005-10-31 2007-05-17 Nakagaki Gijutsushi Jimusho:Kk インターフェロンガンマ発現誘導作用を有する発酵乳、及び発酵乳製造用種菌

Also Published As

Publication number Publication date
RU2010126596A (ru) 2012-01-10
EP2065048A1 (en) 2009-06-03
CN101909643A (zh) 2010-12-08
JP2011505349A (ja) 2011-02-24
EP2224936A1 (en) 2010-09-08
WO2009068997A1 (en) 2009-06-04
US20100284973A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
AR069520A1 (es) Utilizacion de una cepa de l. casei para la preparacion de una composicion para inhibir la activacion de mastocitos
Atassi et al. Diverse expression of antimicrobial activities against bacterial vaginosis and urinary tract infection pathogens by cervicovaginal microbiota strains of Lactobacillus gasseri and Lactobacillus crispatus
Mashima et al. Interaction between Streptococcus spp. and Veillonella tobetsuensis in the early stages of oral biofilm formation
ES2524432T3 (es) Bacterias del ácido láctico como cepas probióticas y composiciones que contienen las mismas
Belizário et al. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches
JP2011505349A5 (es)
Jeong et al. Antimicrobial and anti-biofilm activities of Lactobacillus kefiranofaciens DD2 against oral pathogens
Shen et al. Engineering the gut microbiota to treat hyperammonemia
Chapman et al. In vitro evaluation of single-and multi-strain probiotics: Inter-species inhibition between probiotic strains, and inhibition of pathogens
RU2009133376A (ru) Способы и наборы для введения пробиотиков
Shah et al. Determination of an antimicrobial activity of Weissella confusa, Lactobacillus fermentum, and Lactobacillus plantarum against clinical pathogenic strains of Escherichia coli and Staphylococcus aureus in co-culture
Nunpan et al. Effect of Prebiotics‐Enhanced Probiotics on the Growth of Streptococcus mutans
AR022912A1 (es) Una cepa de las bacterias de acido lactico que forman parte del genero lactobacillus, el uso de la misma para preparar alimentos y las formulacionesalimenticias y farmaceuticas que la contienen
AR024555A1 (es) Composicion dietaria o farmaceutica para ser utilizada en la prevencion o tratamiento de la hiperoxaluria
Kitazawa et al. Probiotics: immunobiotics and immunogenics
Ghasempour et al. Frequency, biofilm formation and acid susceptibility of Streptococcus mutans and Streptococcus sobrinus in saliva of preschool children with different levels of caries activity
Kheadr et al. Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress
Dolati et al. Inhibitory effects of probiotic Bacillus coagulans against MCF7 breast cancer cells
Lee et al. Screening and characterization of lactic acid bacteria strains with anti-inflammatory activities through in vitro and Caenorhabditis elegans model testing
Mahnic et al. Microbiota in vitro modulated with polyphenols shows decreased colonization resistance against Clostridioides difficile but can neutralize cytotoxicity
Miranda et al. Development of a selective culture medium for bifidobacteria, Raffinose-Propionate Lithium Mupirocin (RP-MUP) and assessment of its usage with Petrifilm™ Aerobic Count plates
MXPA04004252A (es) Del genero bifidobacterium y alimentos fermentados que utilizan la misma.
Seo et al. Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence
Dahiya et al. Evaluation of survival, free radical scavenging and human enterocyte adherence potential of lactobacilli with anti‐obesity and anti‐inflammatory CLA isomer‐producing attributes
Dong et al. Lactiplantibacillus plantarum subsp. plantarum and Fructooligosaccharides combination inhibits the growth, adhesion, invasion, and virulence of Listeria monocytogenes

Legal Events

Date Code Title Description
FB Suspension of granting procedure